免疫检查点抑制剂治疗转移性胃癌疗效预测因子

doi:10.3760/cma.j.cn371439-20210104-00095

摘要/Abstract

摘要：

近年来,免疫治疗被更加频繁地用于化疗后进展的转移性胃癌,其中使用最多的是免疫检查点抑制剂(ICI)。然而ICI在不同患者中的疗效差别较大,所以越来越多地开展了关于预测ICI疗效的生物标志物的研究。微卫星不稳定及EB病毒亚型是目前预测ICI治疗反应率相对确切的生物标志物;程序性死亡配体1及肿瘤突变负荷的预测作用仍存在争议;肿瘤浸润淋巴细胞、肿瘤相关巨噬细胞、纤维蛋白样蛋白1、选择性启动子以及其他一些预测因子也正在研究中。

关键词: 胃肿瘤, 免疫疗法, 生物标记

Abstract:

In recent years, immunotherapy has been used more frequently for metastatic gastric cancer that has progressed after chemotherapy, the most commonly used of which are immune checkpoint inhibitors (ICIs). However, the efficacy of ICIs varies greatly among different patients. Therefore, more and more studies have been carried out on biomarkers that predict the efficacy of ICIs. Microsatellite instability and Epstein-Barr virus subtype are relatively accurate biomarkers indicating the response rate of ICIs treatment. The predictive roles of programmed death ligand-1 and tumor mutation burden are still controversial. Tumor infiltrating lymphocyte, tumor-associated macrophages, fibrinogen-like-protein 1, alternative promoters and other predictors are also being studied.

Key words: Gastric neoplasms, Immunotherapy, Biomarkers

胡广越, 殷红, 张慧, 罗宏. 免疫检查点抑制剂治疗转移性胃癌疗效预测因子[J]. 国际肿瘤学杂志, 2021, 48(8): 498-501.

Hu Guangyue, Yin Hong, Zhang Hui, Luo Hong. Efficacy predictors of immune checkpoint inhibitors in the treatment of metastatic gastric cancer[J]. Journal of International Oncology, 2021, 48(8): 498-501.

参考文献 20

[1]	Taghizadeh H, Lampichler K, Beer A, et al. A case report of pseudo-progression after pembrolizumab in metastatic gastric cancer and a review of immunotherapy in gastroesophageal tumors[J]. MEMO, 2019,12:51-59. DOI: 10.1007/s12254-018-0463-4. doi: 10.1007/s12254-018-0463-4
[2]	Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014,513(7517):202-209. DOI: 10.1038/nature13480. doi: 10.1038/nature13480
[3]	Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial [J]. Lancet, 2018,392(10142):123-133. DOI: 10.1016/S0140-6736(18)31257-1. doi: S0140-6736(18)31257-1 pmid: 29880231
[4]	Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020,6(10):1571-1580. DOI: 10.1001/jamaoncol.2020.3370. doi: 10.1001/jamaoncol.2020.3370
[5]	Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular cha-racterization of clinical responses to PD-1 inhibition in metastatic gastric cancer[J]. Nat Med, 2018,24(9):1449-1458. DOI: 10.1038/s41591-018-0101-z. doi: 10.1038/s41591-018-0101-z
[6]	Koemans WJ, Chalabi M, van Sandick JW, et al. Beyond the PD-L1 horizon: in search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma[J]. Cancer Lett, 2019,442:279-286. DOI: 10.1016/j.canlet.2018.11.001. doi: S0304-3835(18)30663-3 pmid: 30419350
[7]	Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial[J]. JAMA Oncol, 2018, 4(5): e180013. DOI 10.1001/jamaoncol.2018.0013. doi: 10.1001/jamaoncol.2018.0013
[8]	Wang F, Wei XL, Wang FH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ⅰb/Ⅱ clinical trial NCT02915432[J]. Ann Oncol, 2019,30(9):1479-1486. DOI: 10.1093/annonc/mdz197. doi: S0923-7534(19)45988-7 pmid: 31987403
[9]	Arora S, Velichinskii R, Lesh RW, et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors[J]. Adv Ther, 2019,36(10):2638-2678. DOI: 10.1007/s12325-019-01051-z. doi: 10.1007/s12325-019-01051-z
[10]	Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors[J]. Adv Anat Pathol, 2017,24(6):311-335. DOI: 10.1097/PAP.0000000000000161. doi: 10.1097/PAP.0000000000000161 pmid: 28777143
[11]	Zhang JY, Zhao YL, Lv YP, et al. Modulation of CD8⁺ memory stem T cell activity and glycogen synthase kinase 3β inhibition enhances anti-tumoral immunity in gastric cancer[J]. Oncoimmunology, 2018,7(4):e1412900. DOI: 10.1080/2162402X.2017.1412900. doi: 10.1080/2162402X.2017.1412900
[12]	Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology[J]. Nat Rev Clin Oncol, 2017,14(7):399-416. DOI: 10.1038/nrclinonc.2016.217. doi: 10.1038/nrclinonc.2016.217 pmid: 28117416
[13]	章盈婧, 于健春. 肿瘤相关巨噬细胞在胃癌发展与治疗中的研究进展[J]. 基础医学与临床, 2019,39(11):1644-1648. DOI: 10.16352/j.issn.1001-6325.2019.11.033. doi: 10.16352/j.issn.1001-6325.2019.11.033
[14]	Qamra A, Xing M, Padmanabhan N, et al. Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma[J]. Cancer Discov, 2017,7(6):630-651. DOI: 10.1158/2159-8290.CD-16-1022. doi: 10.1158/2159-8290.CD-16-1022
[15]	Sundar R, Huang KK, Qamra A, et al. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer[J]. Ann Oncol, 2019,30(3):424-430. DOI: 10.1093/annonc/mdy550. doi: S0923-7534(19)31079-8 pmid: 30624548
[16]	Zhang Y, Qiao HX, Zhou YT, et al. Fibrinogen like protein 1 promotes the invasion and metastasis of gastric cancer and is associated with poor prognosis[J]. Mol Med Rep, 2018,18(2):1465-1472. DOI: 10.3892/mmr.2018.9097. doi: 10.3892/mmr.2018.9097 pmid: 29845203
[17]	Jiang T, Qiao M, Zhao C, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis[J]. Cancer Immunol Immunother, 2018,67(5):713-727. DOI: 10.1007/s00262-018-2126-z. doi: 10.1007/s00262-018-2126-z pmid: 29423649
[18]	Li M, Spakowicz D, Burkart J, et al. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers[J]. Cancer Res Clin Oncol, 2019,145(10):2541-2546. DOI: 10.1007/s00432-019-02982-4. doi: 10.1007/s00432-019-02982-4
[19]	Jin Y, Chen DL, Wang F, et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors[J]. Mol Cancer, 2020,19(1):1-6. DOI: 10.1186/s12943-020-01274-7. doi: 10.1186/s12943-020-01274-7
[20]	Frankel AE, Deshmukh S, Reddy A, et al. Cancer immune checkpoint inhibitor therapy and the gut microbiota[J]. Integr Cancer Ther, 2019,18:1-10. DOI: 10.1177/1534735419846379. doi: 10.1177/1534735419846379